Research becomes a company when the science and the business are built together.
Institutions produce work every year with real commercial potential, and turning that potential into a company is its own discipline with its own timeline. We bring that discipline to your researchers: the commercial thesis, the founding team, the product path and the funding sequence, developed alongside the people who created the science and the office that supports them.
The technical and the commercial are one system. That holds as true for a spinout as for a startup, and the earlier the two are built together, the more of the research's value arrives intact in the market.
Two perspectives, brought to the science at the same time.
Your technology transfer office knows disclosure, protection and licensing, and your researchers know the work better than anyone will again. We add the two views that turn that foundation into a company, and we bring both at once rather than in sequence.
- The builder's perspective
What it takes to run this outside the lab, and how to get there.
- The investor's perspective
What makes this a company investors back, and what to prove first.
What the engagement covers.
Can this research become a company?
- 01
Commercial thesis
The problem the research solves, the people who hold that problem today, and the evidence that they would pay to have it solved.
- 02
Wedge selection
Research usually supports several plausible applications. We work through them with you and choose the one that carries a company, with the reasoning written down.
- 03
Founding team
The shape the team should take: the role the principal investigator wants to hold, where an outside chief executive adds more than they cost, and who carries founder-market fit for this problem.
- 04
Lab to product
The path from research-grade work to a product that can be deployed, maintained and supported by a team beyond its original authors.
- 05
Funding sequence
Which non-dilutive funding carries the work through its next stage, and the point at which equity becomes the right instrument for it.
- 06
Route to market
A clear recommendation between building a venture-scale company and licensing the work, with the reasoning behind it, so the route you take is the one the science supports.
It fits the funding you already hold.
Most of this work happens before a company exists, so engagements are scoped to be payable from the translational, commercialization or industry partnership funding the research already carries. We work with the office that administers the award to shape the scope to what it allows.
A recommendation you can act on either way.
Some research builds a company and some reaches the world faster through a licence, and both are strong outcomes when the choice is made early and for the right reasons. You get a clear recommendation with the evidence behind it, while there is still time for it to shape what happens next.
Thirty minutes with your researchers, your commercialization office, or both. Tell us what the work is and we will tell you what we would examine first.
Book a 30-minute call